-
Product Directory
Custom Product
-
Services Offered
Custom Capabilities
-
Services include biologics safety testing, specialized toxicology and animal health diagnostics
|
Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes |
Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides
Sigma-Aldrich is a leading Life Science and High Technology Materials company focused on enabling science to improve the quality of life
By knowing how our portfolio is organised, you can easily find a product suitable for your application
Request your copy today! Gain access to 3,000 products. Includes inhibitors, activators, agonists, antagonists, modulators and approved drugs
News and Information
St. Louis, MO - January 31, 2012 Sigma-Aldrich Expands Services Offering With BioReliance
Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.
Read MoreSt. Louis, MO - January 9, 2012 Sigma-Aldrich Extends Laboratory Chemicals Contract with Honeywell
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it has signed a five-year contract extension with Honeywell for the manufacture and supply of Riedel-de Haën® high purity solvents, Karl Fischer reagents and other laboratory chemicals produced at Honeywell's Seelze, Germany, manufacturing site. The contract extends an existing supply agreement, in place since 1999, through March 31, 2019.
Read MoreSt. Louis, MO - January 9, 2012 Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has signed an agreement to acquire BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.
Read MoreSt. Louis, MO - December 7, 2011 Sigma® Life Science Announces Gene Knockout Rat Models for Cardiovascular, Diabetes and Atherosclerosis Research
Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE™) Labs, an initiative of Sigma Life Science, has made available three genetically modified rat models that exhibit features key to studying conditions such as obesity, diabetes, atherosclerosis, high cholesterol, hypertension and familial hypercholesterolemia. Details on the models are available at www.sageresearchmodels.com/research-models.
Read More view all press releasesCountry Information
Number of Products Available from Sigma-Aldrich
